QUANTUM BIOPHARMA-B SUB VOT (QNTM) Stock Price & Overview
NASDAQ:QNTM • CA74764Y2050
The current stock price of QNTM is 3.5 USD. Today QNTM is down by -2.51%. In the past month the price decreased by -10.71%. In the past year, price decreased by -24.24%.
QNTM Key Statistics
- Market Cap
- 13.44M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
QNTM Stock Performance
QNTM Stock Chart
QNTM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to QNTM. When comparing the yearly performance of all stocks, QNTM is a bad performer in the overall market: 93.5% of all stocks are doing better.
QNTM Earnings
QNTM Forecast & Estimates
7 analysts have analysed QNTM and the average price target is 31.01 USD. This implies a price increase of 785.97% is expected in the next year compared to the current price of 3.5.
QNTM Groups
Sector & Classification
QNTM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QNTM Ownership
QNTM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.51 | 929.554B | ||
| JNJ | JOHNSON & JOHNSON | 20.63 | 577.341B | ||
| MRK | MERCK & CO. INC. | 21.4 | 288.088B | ||
| PFE | PFIZER INC | 9.01 | 151.297B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 123.651B | ||
| ZTS | ZOETIS INC | 17.68 | 53.866B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.368B | ||
| VTRS | VIATRIS INC | 5.64 | 16.73B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.21 | 11.892B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.259B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.474B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.46B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About QNTM
Company Profile
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Company Info
QUANTUM BIOPHARMA-B SUB VOT
55 University Ave. , Suite 1003
TORONTO ONTARIO CA
Employees: 10
Phone: 14168548884
QUANTUM BIOPHARMA-B SUB VOT / QNTM FAQ
Can you describe the business of QUANTUM BIOPHARMA-B SUB VOT?
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Can you provide the latest stock price for QUANTUM BIOPHARMA-B SUB VOT?
The current stock price of QNTM is 3.5 USD. The price decreased by -2.51% in the last trading session.
Does QNTM stock pay dividends?
QNTM does not pay a dividend.
What is the ChartMill rating of QUANTUM BIOPHARMA-B SUB VOT stock?
QNTM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the number of employees for QUANTUM BIOPHARMA-B SUB VOT?
QUANTUM BIOPHARMA-B SUB VOT (QNTM) currently has 10 employees.
What is the market capitalization of QNTM stock?
QUANTUM BIOPHARMA-B SUB VOT (QNTM) has a market capitalization of 13.44M USD. This makes QNTM a Nano Cap stock.
What is the next earnings date for QNTM stock?
QUANTUM BIOPHARMA-B SUB VOT (QNTM) will report earnings on 2026-03-26.